Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Alnylam's Fitusiran Could Provide Comprehensive Hemophilia Therapy Option

Aug 29 2016

• By Joseph Haas

Color of cells,Particles in liquid.

Related Content

Biogen Hemophilia Spin Out Bioverativ On Track For Early 2017

Aug 09 2016

Shire Backs Hemophilia Focus With Asset Updates, Irish iPATH Study

Jul 27 2016

Hemophilia Market Snapshot: Is There Enough Innovation For Patients To Switch?

Jun 30 2014

Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work

Dec 21 2015

Related Companies

Alnylam Pharmaceuticals Inc.

Takeda Pharmaceutical Co. Ltd.

Biogen, Inc.

uniQure N.V.

Novo Nordisk A/S

Pfizer Inc.

Chugai Pharmaceutical Co., Ltd.

Roche Holding AG

Additional Topics

Clinical Trials Research & Development Companies Blood & Coagulation Disorders BioPharmaceutical

More from Blood and Clotting

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window